Accueil   Diary - News   All news Elsalys Biotech expands its rights on CD 160

Elsalys Biotech expands its rights on CD 160

  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property and signs an exclusive worldwide license in the field of oncology.
  • Thanks to the unique properties of this receptor, ElsaLys Biotech will conduct different antibody programs in these two therapeutic areas.


ElsaLys Biotech, a biopharmaceutical company dedicated to the development of "best-in-disease" therapeutic antibodies for oncology and ophthalmology, announces today the signing with Inserm Transfert of an exclusive worldwide license on the CD160 receptor. This agreement strengthens the rights of the company on this multiple-property target, allowing it to conduct simultaneously three antibodies programs in oncology and ophthalmology.

 



Read the press release

 

 

Elsalys logo_vertical_CMJN